
Tesamorelin
Synthetic GHRH analog. FDA-approved version (Egrifta) indicated for HIV-associated lipodystrophy. Research analog for in vitro study.
Quantity
Bundle & Save
Research Use Only. This product is intended for laboratory research purposes only. Not for human or veterinary use. Not for sale to minors.
Tesamorelin — Key Data
A snapshot of published research on Tesamorelin. Each figure links to the literature summarized below.
How Tesamorelin Works
Tesamorelin is a synthetic GHRH analog with an FDA-approved version (Egrifta) indicated for HIV-associated lipodystrophy. It reduces visceral adipose tissue by 15.2% over 26 weeks, increases IGF-1 by 81%, and has shown cognitive benefits in adults 55-87 (executive function p = .005). It also reduced liver fat by 37% and prevented fibrosis progression (10% vs 37% placebo). For research use only.
Discovered ~2000s100+ publicationsTheratechnologies (Montreal); FDA-approved as Egrifta (2010)
- 01
GHRH Receptor Activation
Primary- Stimulates endogenous GH release from pituitary
- +81% IGF-1 increase (+109 ng/mL in 26 weeks)
- 15.2% visceral fat reduction (n=412, NEJM)
- 02
Hepatic / Cognitive Effects
Secondary- 37% relative liver fat reduction vs placebo
- NAFLD resolution: 35% tesamorelin vs 4% placebo
- Executive function improvement (p = .005) in adults 55-87
What the Studies Show
Peer-reviewed outcomes from published Tesamorelin research.
0
n=412, 2mg SC daily for 26 weeks. vs 5.0% increase in placebo group.
Falutz et al., 2007 (NEJM)Additional Clinical Outcomes
- 0Baker et al., 2012
152 adults aged 55-87 (76 healthy, 61 MCI). 1 mg/day SC for 20 weeks. Overall cognition p = .03 (ITT), p = .002 (completers).
- 0Stanley et al., 2019
12-month study (n=61, HIV+ with NAFLD). Tesamorelin prevented fibrosis progression (p = 0.044). Hepatic fat fraction reduced 37% relative to placebo.
GHRH Analog Comparison
Tesamorelin is the only GHRH analog with FDA approval and published NEJM data
Research Applications
Reported areas of investigation across the Tesamorelin literature.
- 01VISCERAL FAT
15.2% Visceral Fat Reduction (NEJM)
412 patients, 2mg SC daily for 26 weeks. vs 5.0% increase in placebo group. Published in the New England Journal of Medicine.
- VAT reduction
- -15.2%
- Placebo change
- +5.0%
- Patients
- 412
Study finding. IGF-1 increased 81% (+109 ng/mL) over 26 weeks.
Falutz et al., 2007 (NEJM) - 02COGNITIVE FUNCTION
Executive Function Improvement
152 adults aged 55-87 (76 healthy, 61 MCI). 1 mg/day SC for 20 weeks. Executive function p = .005, overall cognition p = .03.
- Executive function
- p = .005
- Overall cognition (ITT)
- p = .03
- Overall (completers)
- p = .002
Study finding. Both healthy adults and those with mild cognitive impairment showed improvement.
Baker et al., 2012 - 03LIVER HEALTH
NAFLD Resolution and Fibrosis Prevention
37% relative liver fat reduction. NAFLD resolution: 35% tesamorelin vs 4% placebo. Fibrosis progression: 10% vs 37% placebo.
- Liver fat reduction
- -37%
- NAFLD resolution
- 35% vs 4%
- Fibrosis progression
- 10% vs 37% (p=0.044)
Study finding. 12-month study (n=61, HIV+ with NAFLD). Tesamorelin prevented fibrosis progression.
Stanley et al., 2019
Reported Observations
- FDA-approved medication (Egrifta) since November 2010
- 34% of patients had IGF-1 SDS >2 at 52 weeks (monitoring required)
- IGF-1 levels maintained at 26-week levels through week 52
This summary reflects observations from published peer-reviewed research. It is not a comprehensive safety assessment. Researchers should review primary literature before designing protocols. For Research Use Only.
Compound Profile
What Is Tesamorelin?
Stability Information
- Protect from light
- Avoid repeated freeze-thaw cycles
- Store in original sealed container
Lyophilized (powder)
up to 2 years
Reconstituted
up to 30 days
Working solution
Use within 24 hours
References
These references are provided for informational purposes. Kern is not affiliated with the authors or institutions listed above.
Related Products
Important Notice — Please Read
The statements made within this website have not been evaluated by the US Food and Drug Administration. The products we offer are not intended to diagnose, treat, cure, or prevent any disease. The peptides sold on this website are intended for research use only. The buyer is responsible for adhering to all local laws and regulations. Kern is not a pharmacy and does not provide medical advice or prescriptions. They are not for human consumption, are not FDA approved, and are not supplements or pharmaceutical drugs. The information provided on this website is for informational purposes and not a substitute for professional medical advice, diagnosis, or treatment. If you have questions or concerns about your health, please talk to your doctor. This site is an advertisement for education, research peptides, and not any specific medication. By purchasing from Kern, you confirm that you are a qualified researcher purchasing these compounds for legitimate in vitro or laboratory research purposes only. You must be 21 years of age or older to purchase.




